Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off an unwelcome bid by Pfizer–or at least drive up the asking price.

…read more

Source: AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline


0 No comments